2243736-45-8
2243736-45-8
Chemical Structure
FB23-2
- CAS No.: 2243736-45-8
- Formula:C18H15Cl2N3O3
- Molecular Weight:392.24
IUPAC Name: 2-((2,6-dichloro-4-(3,5-dimethylisoxazol-4-yl)phenyl)amino)-N-hydroxybenzamide
InChIKey: ILHNIWOZZKIBNW-UHFFFAOYSA-N
SMILES: O=C(NO)C1=CC=CC=C1NC2=C(Cl)C=C(C3=C(C)ON=C3C)C=C2Cl
Biological Activity: FB23-2 is a potent and selective inhibitor of mRNA N6-methyladenosine (m6A) demethylase FTO, with an IC50 of 2.6 μM. FB23-2 has anti-proliferation activity. FB23-2 can be used for the research of acute myeloid leukemia (AML)[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
FB23-2 | 98.55% | FB23-2 is a potent and selective inhibitor of mRNA N6-methyladenosine (m6A) demethylase FTO, with an IC50 of 2.6 μM. FB23-2 has anti-proliferation activity. FB23-2 can be used for the research of acute myeloid leukemia (AML). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
OXFBD02 | 98.04% | OXF BD 02 is a selective inhibitor of BRD4(1) (the first bromodomain of BRD4) with IC50 value of 382 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
OXFBD03 | OXFBD03 serves as an inhibitor of the BRD4(1) protein, which belongs to the bromodomain and extra terminal domain bromodomain family. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GW694481 | GW694481 is an ApoA1 upregulator with IC50 values of 2.1 μM for CYP2C9 inhibition and 17.0 μM for CYP3A4 inhibition. GW694481 upregulates ApoA1 expression in human hepatic cells.GW694481 can be used for the research of atherosclerosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
FB23 | 98.88% | FB23 is a potent and selective FTO demethylase inhibitor with an IC50 of 60 nM. FB23 directly binds to FTO and selectively inhibits FTO's mRNA N6-methyladenosine (m6A) demethylase activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
FTO-IN-1 | FTO-IN-1 is a fat mass and obesity-associated enzyme (FTO) inhibitor extracted from patent WO2018157843A1, compound 32, with an IC50 of <1 μM. FTO-IN-1 can be used for the research of cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
FTO-IN-1 TFA | 98.06% | FTO-IN-1 TFA is a fat mass and obesity-associated enzyme (FTO) inhibitor extracted from patent WO2018157843A1, compound 32, with an IC50 of <1 μM. FTO-IN-1 TFA can be used for the research of cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MptpB-IN-1 | 99.98% | MptpB-IN-1 (Compound 13) is a potent and orally active inhibitor of MptpB. Mycobacterium tuberculosis protein-tyrosine-phosphatase B (MptpB) is a secreted virulence factor that subverts antimicrobial activity in the host. MptpB-IN-1 reduces multidrug-resistant mycobacterium tuberculosis survival and infection burden. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
FTO-IN-7 | 99.22% | FTO-IN-7 (compound 17) is an inhibitor of FTO (fat mass and obesity-associated protein) with an IC50 of <1 μM. FTO-IN-7 can be used for the study of small-cell lung cancers and human bone marrow striated muscle cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ZLD115 | 99.87% | ZLD115 (compound 44) is a FB23-derivated inhibitor of Fat Mass and Obesity-associated Protein (FTO). ZLD115 is an antileukemic agent, exhibiting antiproliferative activity against leukemic cell lines. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dac590 | 96.15% | Dac590 is an orally active and selective obesity-associated protein (FTO) inhibitor with an IC50 of 6.06 nM. Dac590 shows highly selective over ALKBH5 and ALKBH3. Dac590 suppresses oncogenic FTO signaling, induces myeloid differentiation, G1-phase cell cycle arrest, and apoptosis in acute myeloid leukemia (AML) cells. Dac590 inhibits xenograft tumor growth and prolongs survival in acute myeloid leukemia mouse models with no observed toxicity. Dac590 can be used for the research of AML. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
